{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:15:13Z","timestamp":1789758913990,"version":"4.0.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s10067-010-1596-y","type":"journal-article","created":{"date-parts":[[2010,11,2]],"date-time":"2010-11-02T10:19:14Z","timestamp":1288693154000},"page":"303-312","source":"Crossref","is-referenced-by-count":35,"title":["Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology"],"prefix":"10.1007","volume":"30","author":[{"name":"Hong Kong Society of Rheumatology","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Chiu","family":"Mok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai Shan","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak Hin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin K. W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K. M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,3]]},"reference":[{"key":"1596_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/ar2669","volume":"11","author":"SE Gabriel","year":"2009","unstructured":"Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229","journal-title":"Arthritis Res Ther"},{"key":"1596_CR2","first-page":"1133","volume":"20","author":"E Lau","year":"1993","unstructured":"Lau E, Symmons D, Bankhead C et al (1993) Low prevalence of rheumatoid arthritis in the urbanized Chinese of Hong Kong. J Rheumatol 20:1133\u20131137","journal-title":"J Rheumatol"},{"key":"1596_CR3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00296-008-0809-z","volume":"29","author":"YJ Xiang","year":"2009","unstructured":"Xiang YJ, Dai SM (2009) Prevalence of rheumatic diseases and disability in China. Rheumatol Int 29:481\u2013490","journal-title":"Rheumatol Int"},{"key":"1596_CR4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907\u2013916","journal-title":"N Engl J Med"},{"key":"1596_CR5","first-page":"580","volume":"35","author":"E Olech","year":"2008","unstructured":"Olech E, Freeston JE, Conaghan PG et al (2008) Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice. J Rheumatol 35:580\u2013583","journal-title":"J Rheumatol"},{"key":"1596_CR6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"1596_CR7","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588","journal-title":"Ann Rheum Dis"},{"key":"1596_CR8","first-page":"19","volume":"5","author":"CC Mok","year":"2005","unstructured":"Mok CC, for the working group on the use of TNF inhibitors for the treatment of rheumatic diseases in Hong Kong (2005) Consensus statements on the indications and monitoring of anti-tumor necrosis factor (TNF) therapy for rheumatic diseases in Hong Kong. Hong Kong Bull Rheum Dis 5:19\u201325","journal-title":"Hong Kong Bull Rheum Dis"},{"key":"1596_CR9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/ard.2005.044354","volume":"66","author":"B Combe","year":"2007","unstructured":"Combe B, Landewe R, Lukas C et al (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66:34\u201345","journal-title":"Ann Rheum Dis"},{"key":"1596_CR10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0002-9343(01)00872-5","volume":"111","author":"LR Lard","year":"2001","unstructured":"Lard LR, Visser H, Speyer I et al (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111:446\u2013451","journal-title":"Am J Med"},{"key":"1596_CR11","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMra040226","volume":"350","author":"JR O\u2019Dell","year":"2004","unstructured":"O\u2019Dell JR (2004) Therapeutic strategies for Rheumatoid arthritis. N Engl J Med 350:2591\u20132602","journal-title":"N Engl J Med"},{"key":"1596_CR12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate therapy. Arthritis Rheum 54:26\u201337","journal-title":"Arthritis Rheum"},{"key":"1596_CR13","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"EW St Clair","year":"2004","unstructured":"St Clair EW, van der Heijde DM, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432\u20133443","journal-title":"Arthritis Rheum"},{"key":"1596_CR14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263\u2013269","journal-title":"Lancet"},{"key":"1596_CR15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","volume":"146","author":"K Nishimura","year":"2007","unstructured":"Nishimura K, Sugiyama D, Kogata Y et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797\u2013808","journal-title":"Ann Intern Med"},{"key":"1596_CR16","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/1529-0131(200012)43:12<2762::AID-ANR16>3.0.CO;2-#","volume":"43","author":"RJ Wakefield","year":"2000","unstructured":"Wakefield RJ, Gibbon WW, Conaghan PG et al (2000) The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 43:2762\u20132770","journal-title":"Arthritis Rheum"},{"key":"1596_CR17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/BF00197138","volume":"22","author":"L Poleksic","year":"1993","unstructured":"Poleksic L, Zdravkovic D, Jablanovic D, Watt I, Bacic G (1993) Magnetic resonance imaging of bone destruction in rheumatoid arthritis: comparison with radiography. Skeletal Radiol 22:577\u2013580","journal-title":"Skeletal Radiol"},{"key":"1596_CR18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PL (2009) The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am 35:745\u2013757","journal-title":"Rheum Dis Clin North Am"},{"key":"1596_CR19","unstructured":"University Medical Centre Nijmegen. DAS-SCORE.NL. Home of the DAS. Available at: http:\/\/www.das-score.nl\/www.das-score.nl\/ . Accessed 1 June 2010."},{"key":"1596_CR20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/ard.56.8.463","volume":"56","author":"KG Saag","year":"1997","unstructured":"Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA (1997) Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 56:463\u2013469","journal-title":"Ann Rheum Dis"},{"key":"1596_CR21","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/rheumatology\/39.11.1202","volume":"39","author":"B Masdottir","year":"2000","unstructured":"Masdottir B, J\u00f3nsson T, Manfredsdottir V, V\u00edkingsson A, Brekkan A, Valdimarsson H (2000) Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology (Oxford) 39:1202\u20131205","journal-title":"Rheumatology (Oxford)"},{"key":"1596_CR22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/ard.2003.014233","volume":"63","author":"K Forslind","year":"2004","unstructured":"Forslind K, Ahlm\u00e9n M, Eberhardt K, Hafstr\u00f6m I, BARFOT Study Group (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090\u20131095","journal-title":"Ann Rheum Dis"},{"key":"1596_CR23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/ard.57.9.533","volume":"57","author":"T M\u00f6tt\u00f6nen","year":"1998","unstructured":"M\u00f6tt\u00f6nen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Hannonen P (1998) Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with \u201csawtooth\u201d strategy. Ann Rheum Dis 57:533\u2013539","journal-title":"Ann Rheum Dis"},{"key":"1596_CR24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/ard.61.3.270","volume":"61","author":"P Richi","year":"2002","unstructured":"Richi P, Balsa A, Mu\u00f1oz-Fern\u00e1ndez S et al (2002) Factors related to radiological damage in 61 Spaniards with early rheumatoid arthritis. Ann Rheum Dis 61:270\u2013272","journal-title":"Ann Rheum Dis"},{"key":"1596_CR25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.berh.2007.05.007","volume":"21","author":"A Young","year":"2007","unstructured":"Young A, Koduri G (2007) Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:907\u2013927","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1596_CR26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762\u2013784","journal-title":"Arthritis Rheum"},{"key":"1596_CR27","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.berh.2007.05.004","volume":"21","author":"S Lillegraven","year":"2007","unstructured":"Lillegraven S, Kvien TK (2007) Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:827\u2013840","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1596_CR28","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1136\/ard.2004.034371","volume":"64","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Klareskog L, Boers M et al (2005) Comparison of different definitions to classify remission and sustained remission: 1\u00a0year TEMPO results. Ann Rheum Dis 64:1582\u20131587","journal-title":"Ann Rheum Dis"},{"key":"1596_CR29","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","volume":"312","author":"ME Weinblatt","year":"1985","unstructured":"Weinblatt ME, Coblyn JS, Fox DA et al (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818\u2013822","journal-title":"N Engl J Med"},{"key":"1596_CR30","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/art.1780371013","volume":"37","author":"ME Weinblatt","year":"1994","unstructured":"Weinblatt ME, Kaplan H, Germain BF et al (1994) Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 37:1492\u20131498","journal-title":"Arthritis Rheum"},{"key":"1596_CR31","first-page":"S179","volume":"21","author":"T Pincus","year":"2003","unstructured":"Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS (2003) Methotrexate as the \u201canchor drug\u201d for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21:S179\u2013S185","journal-title":"Clin Exp Rheumatol"},{"key":"1596_CR32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/1529-0131(200002)43:2<464::AID-ANR30>3.0.CO;2-U","volume":"43","author":"TR Mikuls","year":"2000","unstructured":"Mikuls TR, O\u2019Dell JR (2000) The changing face of rheumatoid arthritis therapy: results of serial surveys. Arthritis Rheum 43:464\u2013465","journal-title":"Arthritis Rheum"},{"key":"1596_CR33","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.1780331001","volume":"33","author":"DT Felson","year":"1990","unstructured":"Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 33:1449\u20131461","journal-title":"Arthritis Rheum"},{"key":"1596_CR34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","volume":"350","author":"M Boers","year":"1997","unstructured":"Boers M, Verhoeven AC, Markusse HM et al (1997) Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309\u2013318","journal-title":"Lancet"},{"key":"1596_CR35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.10083","volume":"46","author":"RB Landewe","year":"2002","unstructured":"Landewe RB, Boers M, Verhoeven AC et al (2002) COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46:347\u2013356","journal-title":"Arthritis Rheum"},{"key":"1596_CR36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675\u2013681","journal-title":"Lancet"},{"key":"1596_CR37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.7326\/0003-4819-151-9-200911030-00006","volume":"151","author":"A Finckh","year":"2009","unstructured":"Finckh A, Bansback N, Marra CA et al (2009) Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 151:668\u2013669","journal-title":"Ann Intern Med"},{"key":"1596_CR38","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-137-9-200211050-00007","volume":"137","author":"JM Kremer","year":"2002","unstructured":"Kremer JM, Genovese MC, Cannon GW et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726\u2013733","journal-title":"Ann Intern Med"},{"key":"1596_CR39","unstructured":"US Food and Drug Administration (FDA) Web site. FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide). Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm218679.htm . Accessed 31 July 2010."},{"key":"1596_CR40","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","volume":"353","author":"T M\u00f6tt\u00f6nen","year":"1999","unstructured":"M\u00f6tt\u00f6nen T, Hannonen P, Leirisalo-Repo M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. The Lancet 353:1568\u20131573","journal-title":"The Lancet"},{"key":"1596_CR41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253\u2013259","journal-title":"N Engl J Med"},{"key":"1596_CR42","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400\u20131411","journal-title":"Arthritis Rheum"},{"key":"1596_CR43","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","volume":"50","author":"RN Maini","year":"2004","unstructured":"Maini RN, Breedveld FC, Kalden JR et al (2004) Sustained improvement over 2\u00a0years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051\u20131065","journal-title":"Arthritis Rheum"},{"key":"1596_CR44","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologics: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516\u20131523","journal-title":"Ann Rheum Dis"},{"key":"1596_CR45","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini RN, Taylor PC, Szechinski J et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817\u20132829","journal-title":"Arthritis Rheum"},{"key":"1596_CR46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987\u2013997","journal-title":"Lancet"},{"key":"1596_CR47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88\u201396","journal-title":"Ann Rheum Dis"},{"key":"1596_CR48","unstructured":"Kremer J, Fleischmann R, Halland A, et al. (2008) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study [abstract]. Ann Rheum Dis;58:abstr L14."},{"key":"1596_CR49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:865\u2013876","journal-title":"Ann Intern Med"},{"key":"1596_CR50","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.23397","volume":"58","author":"JM Kremer","year":"2008","unstructured":"Kremer JM, Genant HK, Moreland LW et al (2008) Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58:953\u2013963","journal-title":"Arthritis Rheum"},{"key":"1596_CR51","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at 24\u00a0weeks. Arthritis Rheum 54:2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"1596_CR52","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114\u20131123","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"1596_CR53","first-page":"442","volume":"68","author":"JD Isaacs","year":"2009","unstructured":"Isaacs JD, Olech E, Tak PP et al (2009) Autoantibody-positive rheumatoid arthritis (RA) patients (pts) have enhanced clinical response to rituximab (RTX) when compared with seronegative patients. Ann Rheum Dis 68(Suppl 3):442","journal-title":"Ann Rheum Dis"},{"key":"1596_CR54","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","volume":"44","author":"J Keane","year":"2005","unstructured":"Keane J (2005) TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44:714\u2013720","journal-title":"Rheumatology"},{"key":"1596_CR55","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society, Centers for Disease Control and Prevention (2000) This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 161:S221\u2013S247","journal-title":"Am J Respir Crit Care Med"},{"key":"1596_CR56","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","volume":"65","author":"LH Calabrese","year":"2006","unstructured":"Calabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983\u2013989","journal-title":"Ann Rheum Dis"},{"key":"1596_CR57","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1440-1746.2006.04559.x","volume":"21","author":"DM Nathan","year":"2006","unstructured":"Nathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-\u03b1 therapy: Guidelines for clinical approach. J Gastroenterol Hepatol 21:1366\u20131371","journal-title":"J Gastroenterol Hepatol"},{"key":"1596_CR58","doi-asserted-by":"crossref","unstructured":"Matsue K, Kimura SI, Takanashi Y, et al. (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. [Epub ahead of print]","DOI":"10.1002\/cncr.25253"},{"key":"1596_CR59","doi-asserted-by":"crossref","unstructured":"Ji D, Cao J, Hong X, et al. (2010) Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative\/HBcAb-positive: a multicenter retrospective study. Eur J Haematol. [Epub ahead of print]","DOI":"10.1111\/j.1600-0609.2010.01474.x"},{"key":"1596_CR60","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","volume":"54","author":"JH Stone","year":"2006","unstructured":"Stone JH, Holbrook JT, Marriott MA et al (2006) Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54:1608\u20131618","journal-title":"Arthritis Rheum"},{"key":"1596_CR61","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","volume":"64","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421\u20131426","journal-title":"Ann Rheum Dis"},{"key":"1596_CR62","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","volume":"64","author":"P Geborek","year":"2005","unstructured":"Geborek P, Bladstr\u00f6m A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699\u2013703","journal-title":"Ann Rheum Dis"},{"key":"1596_CR63","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","volume":"109","author":"DL Mann","year":"2004","unstructured":"Mann DL, McMurray JJ, Packer M et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594\u20131602","journal-title":"Circulation"},{"key":"1596_CR64","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA (2003) Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133\u20133140","journal-title":"Circulation"},{"key":"1596_CR65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","volume":"9","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group (2010) Autoimmune diseases induced by biologic agents: a double-edged sword? Autoimmun Rev 9:188\u2013193","journal-title":"Autoimmun Rev"},{"key":"1596_CR66","doi-asserted-by":"crossref","unstructured":"Galloway JB, Hyrich KL, Mercer LK, et al. (2010) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6\u00a0months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). [Epub ahead of print]","DOI":"10.1093\/rheumatology\/keq242"},{"key":"1596_CR67","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","volume":"52","author":"J Listing","year":"2005","unstructured":"Listing J, Strangfeld A, Kary S et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403\u20133412","journal-title":"Arthritis Rheum"},{"key":"1596_CR68","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","volume":"56","author":"JR Curtis","year":"2007","unstructured":"Curtis JR, Patkar N, Xie A et al (2007) Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor antagonists. Arthritis Rheum 56:1125\u20131133","journal-title":"Arthritis Rheum"},{"key":"1596_CR69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10165-009-0197-6","volume":"19","author":"R Koike","year":"2009","unstructured":"Koike R, Harigai M, Atsumi T et al (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351\u2013357","journal-title":"Mod Rheumatol"},{"key":"1596_CR70","first-page":"446","volume":"27","author":"EK Schimmel","year":"2009","unstructured":"Schimmel EK, Yazici Y (2009) Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience. Clin Exp Rheumatol 27:446\u2013451","journal-title":"Clin Exp Rheumatol"},{"key":"1596_CR71","first-page":"2167","volume":"33","author":"C Han","year":"2006","unstructured":"Han C, Robinson DW, Hackett MV et al (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. J Rheumatol 33:2167\u20132172","journal-title":"J Rheumatol"},{"key":"1596_CR72","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/ard.2003.018101","volume":"63","author":"C Turesson","year":"2004","unstructured":"Turesson C, Jarenros A, Jacobsson L (2004) Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 63:952\u2013955","journal-title":"Ann Rheum Dis"},{"key":"1596_CR73","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","volume":"107","author":"DH Solomon","year":"2003","unstructured":"Solomon DH, Karlson EW, RImm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303\u20131307","journal-title":"Circulation"},{"key":"1596_CR74","first-page":"36","volume":"30","author":"F Wolfe","year":"2003","unstructured":"Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36\u201340","journal-title":"J Rheumatol"},{"key":"1596_CR75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","volume":"69","author":"MJ Peters","year":"2010","unstructured":"Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325\u2013331","journal-title":"Ann Rheum Dis"},{"key":"1596_CR76","first-page":"838","volume":"23","author":"K Deane","year":"2006","unstructured":"Deane K (2006) Increased prevalence translates into increased fractures\u2014Osteoporosis in RA: a common comorbidity. J Musculoskel Med 23:838\u2013844","journal-title":"J Musculoskel Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10067-010-1596-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T21:14:12Z","timestamp":1559769252000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-010-1596-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,3]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1007\/s10067-010-1596-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,3]]}}}